Affinage

PI4KA

Phosphatidylinositol 4-kinase alpha · UniProt P42356

Length
2102 aa
Mass
236.8 kDa
Annotated
2026-06-10
39 papers in source corpus 22 papers cited in narrative 19 extracted findings
Cross-family judge vs UniProt: tie faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PI4KA (PI4KIIIα) is a type III phosphatidylinositol 4-kinase that generates the predominant plasma membrane pool of PI4P and is the primary enzyme replenishing PI(4,5)P2 during strong stimulation of phospholipase C-coupled receptors, making it essential for plasma membrane lipid homeostasis (PMID:10101268, PMID:24415756). Its catalytic activity resides in a conserved C-terminal kinase domain requiring Lys-1792, which lies adjacent to the ATP-binding site, and Asp-1854 (PMID:11311856, PMID:25855803). At the plasma membrane PI4KA functions within a heterotetrameric assembly with TTC7, FAM126, and the lipidated recruitment adaptor EFR3, whose disordered C-terminus undergoes a disorder-to-order transition to contact both TTC7B and FAM126A, an interface that controls PI4KA membrane recruitment and PI4P output (PMID:34415310, PMID:34415322, PMID:39705356, PMID:38746453, PMID:41197736, PMID:41473329). Recruitment to ER–PM junctions is further driven by Ca²⁺-activated E-Syt1, linking neuronal activity to local PI4P synthesis (PMID:42258130), while calcineurin docks on conserved sites in the PI4KA horn domain and in FAM126A, positioning the phosphatase to regulate the complex by dephosphorylation (PMID:39216471). Through this PI4P-generating activity PI4KA supports plasma membrane localization and signaling of oncogenic KRAS via the EFR3A adaptor and of CXCR4 via TTC7, and its inhibition triggers compensatory RhoB/PLD/phosphatidic acid signaling upon PI4P and phosphatidylserine depletion [PMID:34504076, PMID:37996444, PMID:bio_10.1101_2025.09.30.679611]. Biallelic and missense loss-of-function PI4KA variants that reduce kinase activity or protein levels cause a human spectrum of hypomyelinating leukodystrophy, polymicrogyria with cerebellar hypoplasia, inflammatory bowel disease, intestinal atresia, and combined immunodeficiency (PMID:25855803, PMID:34415310, PMID:34415322, PMID:39885450).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 1999 High

    Established that human PI4KA encodes a large protein whose conserved C-terminal domain confers type III PI 4-kinase enzymatic activity, defining its biochemical identity.

    Evidence In vitro expression in Sf9 cells with enzymatic and pharmacological characterization

    PMID:10101268

    Open questions at the time
    • Did not define cellular substrate pool or in vivo localization
    • No structural model of the catalytic domain
  2. 2001 High

    Identified Lys-1792 as a catalytically essential residue near the ATP-binding site, providing the first active-site landmark for the kinase.

    Evidence Site-directed mutagenesis and FSBA affinity labeling with competitive ATP protection

    PMID:11311856

    Open questions at the time
    • Did not resolve the full catalytic mechanism
    • No co-structure with ATP
  3. 2000 Medium

    Addressed where PI4KA acts in cells, initially localizing it to mitochondrial outer membrane and rough ER in neurons rather than the plasma membrane.

    Evidence Immuno-EM with isoform-specific antibodies in rat brain

    PMID:11045352

    Open questions at the time
    • No functional perturbation linking localization to activity
    • Apparent conflict with later plasma membrane / nucleolar localization unresolved
  4. 2006 Medium

    Detected a nuclease-sensitive nucleolar pool of PI4KA, raising the possibility of functions beyond membrane lipid signaling.

    Evidence Immunofluorescence with siRNA validation, DNase/RNase treatment and detergent extraction

    PMID:17131383

    Open questions at the time
    • No nucleolar function or substrate defined
    • Relationship to cytoplasmic PI4P pools unknown
  5. 2008 Medium

    Mapped the import determinants for the nuclear/nucleolar pool, identifying a classical NLS and a separate nucleolar targeting signal.

    Evidence Digitonin-permeabilized nuclear import assays with synthetic NLS peptides and defined importins

    PMID:18585705

    Open questions at the time
    • No demonstrated function of nuclear-imported PI4KA
    • Physiological regulation of import unknown
  6. 2011 Medium

    Connected PI4KA to a pathogen-driven membrane remodeling event, showing it associates with HCV NS5A to enrich PI4P at the viral membranous web.

    Evidence RNAi silencing, co-IP of PI4KA with NS5A, PI4P imaging at membranous webs

    PMID:22022594

    Open questions at the time
    • Did not establish whether NS5A directly activates the kinase
    • No structural basis for the interaction
  7. 2014 High

    Defined PI4KA's core physiological role as the maintainer of plasma membrane PI4P and replenisher of PI(4,5)P2 during PLC signaling, with loss being lethal.

    Evidence Specific pharmacological inhibitors plus conditional knockout mice with phosphoinositide measurements

    PMID:24415756

    Open questions at the time
    • Did not resolve how the kinase is recruited to the plasma membrane
    • Tissue-specific requirements not fully dissected
  8. 2015 High

    Provided the first catalytic disease residue, showing the polymicrogyria-associated D1854N abolishes kinase activity.

    Evidence In vitro kinase assay of disease mutant plus segregation analysis

    PMID:25855803

    Open questions at the time
    • Did not model how loss of activity causes the specific neurodevelopmental phenotype
  9. 2018 Medium

    Extended PI4KA function to hematopoiesis, linking its catalytic activity to myeloid/erythroid differentiation via multiple signaling pathways.

    Evidence Catalytic-domain inactivation and knockdown with in vitro differentiation and in vivo anemia assays

    PMID:29386109

    Open questions at the time
    • Causal chain from PI4P to AKT/MAPK/SRC/JAK-STAT not directly resolved
    • Direct effectors unidentified
  10. 2021 High

    Established the heterotetrameric PI4KA–EFR3–TTC7–FAM126 complex as the functional plasma membrane PI4P-generating unit and tied biallelic loss-of-function variants to a multisystem human disease spectrum.

    Evidence Two independent patient-cell studies with western blot, lipidomics, structural modeling and exome sequencing

    PMID:34415310 PMID:34415322

    Open questions at the time
    • Did not provide high-resolution structure of the assembled complex
    • Genotype-phenotype determinants across organ systems unclear
  11. 2021 High

    Demonstrated that the EFR3A–PI4KA axis supports oncogenic KRAS plasma membrane localization and signaling, implicating PI4KA in tumorigenesis.

    Evidence KRAS–EFR3A co-IP, EFR3A/PI4KA disruption, lipid and KRAS PM measurements, tethering rescue and xenograft assays

    PMID:34504076

    Open questions at the time
    • Whether KRAS directly modulates kinase activity not shown
    • Generalizability across KRAS-driven tumors untested
  12. 2023 Medium

    Showed PI4KA, via its TTC7 adaptor, supports CXCR4-driven plasma membrane PI4P and prostate cancer invasion, broadening its receptor-coupled signaling roles.

    Evidence CXCR4–TTC7 co-IP, PM PI4P measurement, invasion and in vivo bone tumor models

    PMID:37996444

    Open questions at the time
    • Single co-IP without structural mapping of the CXCR4–TTC7 interface
    • Direct vs indirect coupling unresolved
  13. 2024 High

    Resolved the molecular basis of plasma membrane recruitment, showing the EFR3A C-terminus folds upon binding TTC7B and FAM126A and that this interface harbors disease mutations.

    Evidence Cryo-EM, HDX-MS and interface mutagenesis of the PI4KA–TTC7B–FAM126A–EFR3A assembly

    PMID:38746453 PMID:39705356

    Open questions at the time
    • Dynamics of lipidation-driven membrane targeting not fully captured
    • How modifications toggle the interface in vivo untested
  14. 2024 High

    Identified calcineurin as a direct regulator that docks on conserved sites in PI4KA and FAM126A near phosphorylation sites, implying phosphatase control of the complex.

    Evidence Cryo-EM of a truncated PI4KA–calcineurin complex with HDX-MS

    PMID:39216471

    Open questions at the time
    • Specific phosphosites dephosphorylated by calcineurin not defined
    • Functional consequence on kinase output not directly measured
  15. 2025 High

    Defined a TTC7B-selective nanobody that blocks EFR3 binding and quantified how EFR3 phosphorylation and isoform identity tune complex affinity and PI4KA membrane recruitment.

    Evidence Cryo-EM, HDX-MS, nanobody selection, affinity measurements and bilayer/cell PI4P assays

    PMID:41197736 PMID:41473329

    Open questions at the time
    • In vivo relevance of EFR3 isoform affinity differences not established
    • Kinase that phosphorylates EFR3 not identified here
  16. 2025 Medium

    Characterized additional disease alleles affecting catalysis and splicing, reinforcing that both catalytic-domain integrity and correct splicing are required for PI4KA function.

    Evidence Minigene splicing assay and in vitro kinase activity of purified mutant fragments

    PMID:39885450

    Open questions at the time
    • Single case study
    • Cellular and clinical impact of partial activity loss not quantified
  17. 2026 Medium

    Connected Ca²⁺ signaling to PI4KA membrane recruitment, showing E-Syt1 delivers ER-localized PI4KA to ER–PM junctions to drive activity-dependent PI4P synthesis in neurons.

    Evidence Live-cell imaging, Ca²⁺ stimulation, E-Syt1 perturbation and PM PI4P biosensors in hippocampal neurons

    PMID:42258130

    Open questions at the time
    • Direct physical contact between E-Syt1 and PI4KA not structurally defined
    • Relationship to EFR3-mediated recruitment unclear

Open questions

Synthesis pass · forward-looking unresolved questions
  • How PI4P depletion is sensed to trigger compensatory lipid remodeling, and how phosphorylation and calcineurin dephosphorylation are integrated to set PI4KA output in vivo, remain unresolved.
  • Compensatory RhoB/PLD/PA pathway described only in a preprint
  • No unified model linking calcineurin regulation, EFR3 phosphorylation and Ca²⁺-driven recruitment
  • Function of the nuclear/nucleolar pool unexplained

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 4 GO:0140657 ATP-dependent activity 2
Localization
GO:0005886 plasma membrane 4 GO:0005730 nucleolus 2 GO:0005783 endoplasmic reticulum 2 GO:0005739 mitochondrion 1
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 3 R-HSA-1430728 Metabolism 2
Partners
CALCINEURIN (PPP3)CXCR4E-SYT1EFR3AEFR3BFAM126AKRASTTC7B
Complex memberships
PI4KA–TTC7–FAM126–EFR3 heterotetramer

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 Human PI4KA (PI4K230) encodes a 2044-amino acid protein with a C-terminal catalytic domain (~260 aa) that is highly conserved among PI 4-kinases. When expressed in vitro and in Sf9 cells, it exhibits type III PI 4-kinase characteristics: not inhibited by adenosine, high Km for ATP (~300 µM), half-maximally inactivated by ~200 nM wortmannin, and specific activity of 58 µmol mg⁻¹ min⁻¹. In vitro expression, enzymatic activity assays, pharmacological characterization Biochimica et biophysica acta High 10101268
2001 The conserved Lys-1792 in the catalytic domain of PI4K230 (PI4KA) is essential for enzymatic activity and serves as a target of affinity labeling by the ATP-analog FSBA. ATP and ATP analogues competitively protect against FSBA inactivation, confirming this residue's proximity to the ATP-binding site. Site-directed mutagenesis, affinity labeling with FSBA, enzymatic activity assays The international journal of biochemistry & cell biology High 11311856
2000 PI4K230 (PI4KA) localizes in neurons predominantly to the outer membrane of mitochondria and membranes of the rough endoplasmic reticulum, and is also co-localized with some multivesicular bodies. No nuclear or plasma membrane localization was detected, suggesting its role in intracellular vesicular traffic rather than direct ligand-stimulated phosphoinositide turnover at the plasma membrane. Immunocytochemistry (light and electron microscopy) with isoform-specific antibodies in rat brain sections Experimental brain research Medium 11045352
2006 PI4K230 (PI4KA) is detected in the nucleolus of multiple mammalian cell types, forming a Triton X-100-resistant, DNase- and RNase-sensitive complex there. siRNA knockdown of PI4K230 abolishes the nucleolar signal, confirming specificity. Immunofluorescence on ethanol-fixed cells and cryosections, siRNA knockdown, DNase/RNase treatments, Triton X-100 extraction Cytometry. Part A Medium 17131383
2008 PI4KA contains a functional monopartite NLS (NLS1: residues 916–934) that directs nuclear import via importin α1 and α3 (but not α5) through the classical importin α/β mechanism. A separate bipartite NLS2 (residues 1414–1433) functions as a nucleolar targeting signal and can mediate nuclear import via importin α1/β or α3/β complexes when present in a larger fragment (AA1166–1667). Digitonin-permeabilized HeLa cell nuclear import assays, fluorescent BSA conjugates with synthetic NLS peptides, molecular modeling, importin binding experiments Experimental cell research Medium 18585705
2011 PI4KA is required for local enrichment of phosphatidylinositol 4-phosphate (PI4P) at the HCV membranous web and for morphologically normal web formation. PI4KA physically associates with NS5A in HCV-infected cells, whereas the related kinase PI4KB does not interact with NS5A and does not affect web morphology or PI4P enrichment upon silencing. RNAi silencing, co-immunoprecipitation (PI4KA with NS5A), immunofluorescence/confocal microscopy of PI4P at membranous webs, non-replicative web formation model PloS one Medium 22022594
2014 PI4KA is the primary enzyme maintaining plasma membrane PI4P pools and is essential for replenishing PI(4,5)P2 specifically during strong stimulation of phospholipase C-coupled receptors. Pharmacological inhibition of PI4KA in adult mice causes sudden death correlating with PI(4,5)P2 depletion after agonist stimulation; conditional genetic knockout causes severe intestinal necrosis and death. Highly specific PI4KA inhibitors (pharmacological), conditional knockout mice, phosphoinositide level measurements after PLC stimulation The Journal of biological chemistry High 24415756
2015 A missense substitution p.D1854N in the catalytic domain of PI4KA, identified in patients with polymicrogyria and cerebellar hypoplasia, abolishes kinase activity, demonstrating that residue D1854 is essential for PI4KA catalytic function. Expression of wild-type and mutant PI4KA with in vitro kinase activity assay; Sanger sequencing confirmation of segregation Human molecular genetics High 25855803
2021 PI4KA forms a heterotetrameric complex with EFR3, TTC7, and FAM126 at the plasma membrane to generate PI4P. Biallelic loss-of-function PI4KA variants reduce PI4KA protein levels, decrease PI4KA catalytic activity (assessed by immunofluorescence and targeted lipidomics in patient fibroblasts and PBMCs), and cause hypomyelinating leukodystrophy, inflammatory bowel disease, intestinal atresia, and combined immunodeficiency in humans. Western blotting, immunofluorescence, targeted lipidomics in patient-derived fibroblasts and PBMCs; structural modelling of complex interfaces; exome sequencing Brain : a journal of neurology High 34415310 34415322
2021 Oncogenic KRAS preferentially binds EFR3A (the PI4KA plasma membrane recruitment adaptor). Disrupting EFR3A or PI4KA reduces PI4P, phosphatidylserine, and KRAS levels at the plasma membrane, diminishing oncogenic signaling and tumorigenesis. Tethering PI4KA directly to the plasma membrane rescues these phenotypes, demonstrating that EFR3A-PI4KA axis supports KRAS plasma membrane localization and signaling. Co-immunoprecipitation (KRAS–EFR3A), siRNA/genetic disruption of EFR3A and PI4KA, PI4P and phosphatidylserine lipid measurements at PM, KRAS PM localization assays, PI4KA tethering rescue experiment, xenograft tumor assays Nature communications High 34504076
2023 CXCR4 binds to PI4KA adaptor protein TTC7, and this interaction drives plasma membrane PI4P production in prostate cancer cells. Inhibiting PI4KA or TTC7 reduces PM PI4P production, cellular invasion, and bone tumor growth. Co-immunoprecipitation (CXCR4–TTC7), PI4P measurement at plasma membrane, invasion assays, in vivo bone tumor models with PI4KA/TTC7 inhibition Scientific reports Medium 37996444
2024 The C terminus of EFR3A undergoes a disorder-to-order transition upon binding to the PI4KA–TTC7B–FAM126A heterotrimer, directly contacting both TTC7B and FAM126A. Mutations disrupting this interface reduce PI4KA recruitment to the plasma membrane. Multiple disease-linked mutations and post-translational modifications map to this binding site. Cryo-EM structure determination, hydrogen-deuterium exchange mass spectrometry (HDX-MS), mutational analysis of complex interface Science advances High 38746453 39705356
2024 Calcineurin (CNAβ1 isoform) directly binds to PI4KA via an evolutionarily conserved IKISVT sequence in PI4KA's horn domain, and also binds FAM126A via conserved LTLT and PSISIT sequences. These dual calcineurin-binding sites are in close proximity to phosphorylation sites in the PI4KA complex, suggesting calcineurin regulates PI4KA through dephosphorylation of the complex. Cryo-EM structure of truncated PI4KA complex with calcineurin, HDX-MS, computational analysis of binding interfaces Structure High 39216471
2018 Targeted inactivation of the Pi4ka catalytic domain or reduction in Pi4ka mRNA expression inhibits myeloid and erythroid cell differentiation in vitro and promotes anemia in vivo. The mechanism involves deregulation of AKT, MAPK, SRC, and JAK-STAT signaling pathways downstream of Pi4ka activity. Catalytic domain inactivation, mRNA knockdown, in vitro differentiation assays, in vivo anemia model, signaling pathway analysis (AKT, MAPK, SRC, JAK-STAT) Cell reports Medium 29386109
2022 PI4KA forms a stable complex with TTC7 and FAM126; a novel PI4KA inhibitor (cepharanthine) undermines the stability of this PI4KA/TTC7/FAM126 complex. PI4KA depletion sensitizes drug-resistant leukemia cells to chemotherapy by regulating the ERK/AMPK/OXPHOS axis. LC-MS, ELISA kinase assay, MM/GBSA binding analysis, siRNA knockdown, in vitro and in vivo leukemia models Theranostics Medium 36276647
2025 A TTC7B-selective nanobody was developed that sterically blocks EFR3 binding to TTC7B in PI4KA complexes. EFR3B phosphorylation markedly decreases its binding affinity to TTC7-FAM126. EFR3A-TTC7B-FAM126A binds with ~10-fold higher affinity than most other EFR3-TTC7-FAM126 combinations. Nanobody binding causes decreased PI4KA membrane recruitment on lipid bilayers and in cells, with decreased PM PI4P production. Cryo-EM, HDX-MS, yeast display nanobody selection, binding affinity measurements, lipid bilayer recruitment assay, cell-based PM PI4P measurement The Journal of biological chemistry High 41197736 41473329
2026 In response to Ca2+ signaling, the ER membrane tethering protein E-Syt1 recruits ER-localized PI4KA to ER-PM junctions, facilitating PI4KA's plasma membrane recruitment and assembly of the PI4KA enzyme complex, thereby enhancing PM PI4P synthesis. In hippocampal neurons, neuronal activity-induced PM localization of PI4KA and PM PI4P synthesis depend on E-Syt1 function. Live cell imaging of PI4KA localization, Ca2+ stimulation experiments, E-Syt1 knockdown/knockout, PI4P biosensor measurements at PM, hippocampal neuron synaptic potentiation assays Science China. Life sciences Medium 42258130
2025 PI4KA inhibition reduces PM PI4P levels, which triggers a compensatory increase in phospholipase D (PLD) activity and phosphatidic acid (PA) levels at the PM. This is mediated by a concomitant decrease in phosphatidylserine (PS) levels upon PI4P depletion, activating a reciprocal relationship between PS synthesis and PLD-mediated PA generation. Additionally, loss of PM PI4P upregulates the small GTPase RhoB transcriptionally and translationally, which further enhances PLD-mediated PA synthesis and actin cytoskeletal remodeling. Pharmacological PI4KA inhibition, RNA-seq, proximity labeling proteomics, lipid measurements (PI4P, PS, PA), RhoB protein/mRNA quantification, PLD activity assays bioRxivpreprint Medium bio_10.1101_2025.09.30.679611
2025 The PI4KA variant c.2819C>T (p.Ala940Val) significantly reduces PI4KA enzyme activity when assessed using purified mutant protein fragments, and a deletion variant c.2802_2863-40del produces three distinct aberrant mRNA isoforms via splicing disruption, together demonstrating catalytic domain and splice-site requirements for PI4KA function. Minigene splicing assay, purification of recombinant wild-type and mutant PI4KA fragments, in vitro kinase activity measurement BMC medical genomics Medium 39885450

Source papers

Stage 0 corpus · 39 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2014 Pharmacological and genetic targeting of the PI4KA enzyme reveals its important role in maintaining plasma membrane phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate levels. The Journal of biological chemistry 162 24415756
2007 An association screen of myelin-related genes implicates the chromosome 22q11 PIK4CA gene in schizophrenia. Molecular psychiatry 89 17893707
2011 The role of the phosphatidylinositol 4-kinase PI4KA in hepatitis C virus-induced host membrane rearrangement. PloS one 73 22022594
2015 Germline recessive mutations in PI4KA are associated with perisylvian polymicrogyria, cerebellar hypoplasia and arthrogryposis. Human molecular genetics 66 25855803
2021 Biallelic PI4KA variants cause neurological, intestinal and immunological disease. Brain : a journal of neurology 43 34415310
2021 Biallelic PI4KA variants cause a novel neurodevelopmental syndrome with hypomyelinating leukodystrophy. Brain : a journal of neurology 42 34415322
2021 Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity. Nature communications 41 34504076
2009 Association of the PIK4CA schizophrenia-susceptibility gene in adults with the 22q11.2 deletion syndrome. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 37 18646052
1999 Functional expression and characterisation of a new human phosphatidylinositol 4-kinase PI4K230. Biochimica et biophysica acta 35 10101268
2000 Immunohistochemical localisation of two phosphatidylinositol 4-kinase isoforms, PI4K230 and PI4K92, in the central nervous system of rats. Experimental brain research 29 11045352
2006 Nucleolar localization of phosphatidylinositol 4-kinase PI4K230 in various mammalian cells. Cytometry. Part A : the journal of the International Society for Analytical Cytology 25 17131383
2003 Polymorphism screening of PIK4CA: possible candidate gene for chromosome 22q11-linked psychiatric disorders. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 24 12497619
2023 PI4KA and PIKfyve: Essential phosphoinositide signaling enzymes involved in myriad human diseases. Current opinion in cell biology 21 37453227
2018 A Forward Genetic Screen Targeting the Endothelium Reveals a Regulatory Role for the Lipid Kinase Pi4ka in Myelo- and Erythropoiesis. Cell reports 17 29386109
2024 Molecular basis for plasma membrane recruitment of PI4KA by EFR3. Science advances 13 39705356
2008 Nuclear and nucleolar localization signals and their targeting function in phosphatidylinositol 4-kinase PI4K230. Experimental cell research 13 18585705
2023 Structural basis for the conserved roles of PI4KA and its regulatory partners and their misregulation in disease. Advances in biological regulation 12 37979461
2022 Targeting PI4KA sensitizes refractory leukemia to chemotherapy by modulating the ERK/AMPK/OXPHOS axis. Theranostics 12 36276647
2022 Human CPTP promotes growth and metastasis via sphingolipid metabolite ceramide and PI4KA/AKT signaling in pancreatic cancer cells. International journal of biological sciences 11 35982909
2014 Synergistic association of PI4KA and GRM3 genetic polymorphisms with poor antipsychotic response in south Indian schizophrenia patients with low severity of illness. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 11 25209194
2024 Biallelic PI4KA Mutations Disrupt B-Cell Metabolism and Cause B-Cell Lymphopenia and Hypogammaglobulinemia. Journal of clinical immunology 10 39312004
2001 The ATP-binding site of brain phosphatidylinositol 4-kinase PI4K230 as revealed by 5'-p-fluorosulfonylbenzoyladenosine. The international journal of biochemistry & cell biology 9 11311856
2024 Structure of calcineurin bound to PI4KA reveals dual interface in both PI4KA and FAM126A. Structure (London, England : 1993) 8 39216471
2023 Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth. Scientific reports 7 37996444
2025 TTC7B triggers the PI4KA-AKT1-RXRA-FTO axis and inhibits colon cancer cell proliferation by increasing RNA methylation. International journal of biological sciences 5 39897037
2001 Synthesis of new cyclitol compounds that influence the activity of phosphatidylinositol 4-kinase isoform, PI4K230. Journal of medicinal chemistry 5 11170653
2024 Two Novel Variants in PI4KA in a Family Presenting With Hereditary Spastic Paraparesis: A Case Report. Neurology. Genetics 4 38685974
2021 Sevoflurane Suppresses Colon Cancer Cell Malignancy by Regulating circ-PI4KA. OncoTargets and therapy 4 34045869
2016 Derivation of original RESP atomic partial charges for MD simulations of the LDAO surfactant with AMBER: applications to a model of micelle and a fragment of the lipid kinase PI4KA. Journal of biomolecular structure & dynamics 4 26998712
2009 Association study between the PIK4CA gene and methamphetamine use disorder in a Japanese population. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 4 18521859
2023 Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth. Research square 2 36865146
2024 Molecular basis for plasma membrane recruitment of PI4KA by EFR3. bioRxiv : the preprint server for biology 1 38746453
2026 Pi4ka downregulation triggers Creb3l2-dependent lysosomal dysfunction to promote maladaptive tubular remodeling and immune activation in acute kidney injury. Cell death & disease 0 42045152
2026 [Analysis of PI4KA gene variants in a patient with Hereditary spastic paraplegia type 84]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 0 42091194
2026 E-Syt1 recruits PI4KA to endoplasmic reticulum-plasma membrane junctions to enhance PI4P synthesis. Science China. Life sciences 0 42258130
2025 Identifying novel heterozygous PI4KA variants in fetal abnormalities. BMC medical genomics 0 39885450
2025 A phosphatidylinositol 4-kinase alpha (PI4KA) gene reduces plant height of common wheat. Gene 0 40348068
2025 Development of an inhibitory TTC7B selective nanobody that blocks EFR3 recruitment of PI4KA. The Journal of biological chemistry 0 41197736
2025 Development of an inhibitory TTC7B selective nanobody that blocks EFR3 recruitment of PI4KA. bioRxiv : the preprint server for biology 0 41473329

Missed literature

Know a paper Affinage missed for PI4KA? Flag it for the maintainers and the community.

No submissions yet.